Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PARP15 | Q460N3 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | DAO | P14920 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307689 | 0.77 | PARP1 (0.62) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL14027180 | 0.77 | PARP1 (0.62) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL30033470 | 0.75 | PARP1 (0.60) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL1536658 | 0.75 | PARP1 (0.60) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL29519573 | 0.75 | PARP1 (1.00) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL31743106 | 0.75 | PARP1 (0.60) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL2172575 | 0.75 | PARP1 (1.00) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL12463821 | 0.75 | PARP1 (0.60) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL832144 | 0.75 | PARP1 (0.60) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL29492688 | 0.75 | PARP1 (1.00) | PARP1ALDH1A1HSD17B10KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025109076-A1 | BIOMARKERS FOR IDENTIFYING PATIENTS HAVING TUMORS WITH HOMOLOGOUS RECOMBINATION DEFICIENCY | INSTITUT CURIE (FR) | 2025-05-30 | — | — | WO | claimed |
| EP-1807117-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING COMPOSITIONS COMPRISING AN INHIBITOR OF ENDOTHELIN RECEPTOR ACTIVITY | The California Institute of Technology (US) | 2007-07-18 | — | — | EP | claimed |
| WO-2006050026-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING COMPOSITIONS COMPRISING AN INHIBITOR OF ENDOTHELIN RECEPTOR ACTIVITY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-05-11 | — | — | WO | claimed |
| US-20060094676-A1 | Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2006-05-04 | — | — | US | claimed |
| US-20250381221-A1 | Compositions and Methods for Treating Cancer | IN8BIO INC (US) | 2025-12-18 | — | — | US | disclosed |
| WO-2025109076-A1 | BIOMARKERS FOR IDENTIFYING PATIENTS HAVING TUMORS WITH HOMOLOGOUS RECOMBINATION DEFICIENCY | INSTITUT CURIE (FR) | 2025-05-30 | — | — | WO | disclosed |
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4554683-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | Lantern Pharma Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON | 2025-04-03 | — | — | US | disclosed |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240245643-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-25 | — | — | US | disclosed |
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2002069910-A2 | USE OF SUBSTANCES THAT PREVENT THAT THE NO SYNTHASE OF WARM-BLOODED ORGANISMS TAKES EFFECT, FOR PRODUCING COSMETIC OR DERMATOLOGICAL PREPARATIONS FOR THE TREATMENT AND/OR THE PROPHYLAXIS OF UNDESIRED SKIN PIGMENTATION | BEIERSDORF AG (DE) | 2002-09-12 | — | — | WO | disclosed |
| US-4847264-A | ANTIULCER AGENTS, ANTISECRETORY AGENTS | RORER PHARMACEUTICAL CORPORATION (US) | 1989-07-11 | — | — | US | disclosed |
| US-4632927-A | ANTISECRETORY, ANTIULCER AGENTS | WILLIAM H. RORER, INC. (US) | 1986-12-30 | — | — | US | disclosed |
| EP-0113782-A4 | BICYCLIC NITROGEN HETEROCYCLIC ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES. | RORER INTERNAT OVERSEAS INC (US) | 1986-03-18 | — | — | EP | disclosed |
| EP-0113782-A1 | BICYCLIC NITROGEN HETEROCYCLIC ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1984-07-25 | — | — | EP | disclosed |
| WO-1984000544-A1 | BICYCLIC NITROGEN HETEROCYCLIC ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES | RORER INT OVERSEAS (US) | 1984-02-16 | — | — | WO | disclosed |
| US-4065456-A | CNS DEPRESSANTS | OTSUKA PHARMACEUTICAL CO., LTD. (JA) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | PARP1, PARP2, PARP3 | PARP1 1/4885ALDH1A1 1781/4885HSD17B10 2525/4885 |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | PARP1, PARP2, PARP11 | PARP1 1/4885ALDH1A1 1466/4885HSD17B10 2127/4885 |
| US-20240245643-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | PARP2, MRE11, PARP1 | PARP1 3/4885ALDH1A1 747/4885HSD17B10 666/4885 |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | DHFR, CCNH, ODC1 | PARP1 1250/4885ALDH1A1 4524/4885HSD17B10 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.